Project Details
Projekt Print View

Metmorfin as adjuvant therapy for glioblastoma - a pathway to clinical phase I/II-trials

Subject Area Hematology, Oncology
Term from 2014 to 2017
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 190230491
 
Final Report Year 2019

Final Report Abstract

Use of metformin is not associated with a reduced risk of glioma, but patients with specific glioma subtypes (i.e. WHO grade III glioma, possibly IDH-mutated gliomas, patients with a proneural signature) may be more responsive to treatment with metformin. Adding rationale combination partners may augment inhibitory effects of metformin on glioma. Future clinical trials should consider subtype specific responses and combinatorial approaches.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung